Severe Psoriasis - Pipeline Review, H1 2015

05:00 EDT 8 Jun 2015 | BioPortfolio Reports

Recently added to the BioPortfolio report store, Severe Psoriasis - Pipeline Review, H1 2015 is a new report from Global Markets Direct published on 2015-04-28. This 110-page report is available in PDF from $2000.

Severe Psoriasis - Pipeline Review, H1 2015


Global Markets Direct’s, ‘Severe Psoriasis - Pipeline Review, H1 2015’, provides an overview of the Severe Psoriasis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Severe Psoriasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Severe Psoriasis and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


- The report provides a snapshot of the global therapeutic landscape of Severe Psoriasis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Severe Psoriasis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Severe Psoriasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Severe Psoriasis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of…

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Severe Psoriasis Overview 8
Therapeutics Development 9
Pipeline Products for Severe Psoriasis - Overview 9
Pipeline Products for Severe Psoriasis - Comparative Analysis 10
Severe Psoriasis - Therapeutics under Development by Companies 11
Severe Psoriasis - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Severe Psoriasis - Products under Development by Companies 14
Severe Psoriasis - Companies Involved in Therapeutics Development 16
Almirall, S.A. 16
Amgen Inc. 17
ApoPharma Inc. 18
Boehringer Ingelheim GmbH 19
Covagen AG 20
Eli Lilly and Company 21
Idera Pharmaceuticals, Inc. 22
Johnson & Johnson 23
Merck KGaA 24
Pfizer Inc. 25
Sandoz International GmbH 26
Sun Pharmaceutical Industries Inc. 27
Syntrix Biosystems, Inc. 28
UCB S.A. 29
Valeant Pharmaceuticals International, Inc. 30
XenoPort, Inc. 31
Severe Psoriasis - Therapeutics Assessment 32
Assessment by Monotherapy Products 32
Assessment by Target 33
Assessment by Mechanism of Action 35
Assessment by Route of Administration 37
Assessment by Molecule Type 39
Drug Profiles 41
adalimumab biosimilar - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
adalimumab biosimilar - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
aminopterin sodium - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
baricitinib - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
BI-655066 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
brodalumab - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
certolizumab pegol - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
COVA-322 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
dimethyl fumarate - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
etanercept biosimilar - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
guselkumab - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
IDP-118 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
IMO-8400 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
ixekizumab - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
MSB-0010841 - Drug Profile 67
For more information open Severe Psoriasis - Pipeline Review, H1 2015.


Original Article: Severe Psoriasis - Pipeline Review, H1 2015


More From BioPortfolio on "Severe Psoriasis - Pipeline Review, H1 2015"

Quick Search


Relevant Topics

BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...

Psoriasis is a common skin condition affecting 2-3% of the population of the United Kingdom, where the skins replacement process is sped taking 2-6 days instead of the usual 21 - 28 days for the replacement of skin cells. Patients experience an accumulat...

Alzumab (Itolizumab)
Biocon Launches ALZUMAb™ - a ‘First in Class’ Novel Biologic Treatment for Psoriasis Patients in India • ALZUMAb™-World's first novel anti-CD6 antibody developed by Biocon to address a large unmet need for th...